On 4 June 2020, orphan designation EU/3/20/2280 was granted by the European Commission to Nordic Nanovector ASA, Norway, for lutetium (177Lu) lilotomab satetraxetan (also known as Betalutin) for the treatment of marginal zone lymphoma.
Lutetium (177Lu) lilotomab satetraxetan
Treatment of marginal zone lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: